By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A majority of Osmetech's shareholders have approved the firm's plans to proceed with an initial public offering and other proposals, according to a notice posted on the London Stock Exchange.

Last month, Osmetech said that it had filed with the US Securities and Exchange Commission for the IPO under the name of its newly proposed parent, GenMark Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.